Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
NEW YORK, Dec 22 (Reuters) - UnitedHealth Group (UNH.N) agreed on Friday to sell its Brazilian health insurance operator Amil to businessman Jose Seripieri Filho, two sources with knowledge of the matter said.
STADA and Alvotech receive positive CHMP opinion for ustekinumab biosimilar
Speculation that Stada Arzneimittel may be looking for a buyout has largely been confirmed after the company’s CEO said as much in a recent German-language news story.
Stada`s Kinpeygo (budesonide) Receives Approval in Europe
Bad Vilbel – 12 July 2023 – STADA is significantly expanding its European Consumer Healthcare portfolio by acquiring another range of well-established and leading local and regional consumer healthcare brands from Sanofi in European countries, including Belgium, Germany, Hungary, Spain and the United Kingdom, as well as Nordic countries. The transaction covers several brands, including: Antistax for pain relief and tiredness in legs; the allergy eye drops Lomudal; Omnivit vitamins; and Opticrom allergy eye drops. In addition, the two painkillers AAS and Dolalgial, as well as Bila-Git for gallbladder complaints, are part of the acquired portfolio. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities.
Following a six-day inspection of the Norbitec biologics facility in Uetersen, Germany, the US Food and Drug Administration (FDA) has approved the STADA-controlled entity as a manufacturing and storage site for Retacrit (epoetin alfa-epbx) drug substance, an important therapy for anemia associated with chemotherapy and chronic kidney disease that has annual US sales in excess of US$ 300 million.